Amarin (AMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The Zack ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 10: Amarin Corporation plc (AMRN) : This pharmaceuticals company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 50% over the last 60 days. UiPath Inc. (PATH) : This robotic process automation company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.8% overthe last 60 days. UiPath's share ...

Amarin Corporation (AMRN) reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of 2 cents per share in the year-ago quarter.Excluding stock-based compensation expense and the American Depositary Shares (“ADS”) ratio change fees, the company incurred an adjusted loss of 2 cents per share in the first quarter of 2025 compared with an adjusted loss of 1 cent reported in the year ...

Amarin Corporation (AMRN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Marmur - VP, Global Corporate Comunications & IRAaron Berg - CEO, President & DirectorPeter Fishman - SVP & CFOAdam Ferrarini - Biotech Equity Research AssociateSteven Ketchum - Executive VP, President of Research & Development and Chief Scientific Officer Conference Call Participants None - Analyst Operator Welcome to Amarin Corporation's conference call to discuss its first quarter twenty twenty five busines ...

Amarin Corporation (AMRN) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Welcome to Amarin Corporation's conference call to discuss its first quarter twenty twenty five business update and financial results. I would like to turn the conference call over to Mark Marmer, Vice President, Corporate Communications and Investor Relations at Amarin. Speaker1 Good morning, everyone, and thank you for joining us. Turning to slide two and our forward looking statements. Please be aware that this conference c ...

First Quarter 2025 Financial Results & Business Update Conference Call May 7, 2025 Forward-Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches,research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Registrant's telephone number, including area code: +353 (0) 1 6699 020 Securities registered pursuant to Section 12(b) of the Act: | Ti ...

Exhibit 99.1 Amarin Reports First Quarter 2025 Financial Results Europe • The Company generated revenue of $35.7 million from branded VASCEPA despite numerous generic versions of the product currently available. The U.S. business remains profitable and continues to generate cash. • The Company retained all major exclusive accounts through the first quarter, which forms the basis for a majority of U.S. product sales and margin. • The Company has prepared a plan for an authorized generic (AG) version of VASCE ...

-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA/VAZKEPA -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- Total net revenue for the three months ended March 31, 2025 was $42.0 million, compared to $56.5 million in the corresponding period of 2 ...

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation ...